Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential

Vaccine

Volumn 24, Issue 47-48, 2006, Pages 6859-6866

  Desheva, J A ^a   Lu, X H ^b   Rekstin, A R ^a   Rudenko, L G ^a   Swayne, D E ^c   Cox, N J ^b   Katz, J M ^b   Klimov, A I ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Avian influenza vaccine; Influenza pandemic; Mouse model

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; AVIAN INFLUENZA; CHICKEN; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; CHICKENS; CROSS REACTIONS; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRUS REPLICATION;

EID: 33846240928     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.023     Document Type: Article

References (40)

1. Claas E.C.J., Osterhaus A.D.M.E., Van Beek R., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 (1998) 472-477
2. Subbarao K., Klimov A., Katz J., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998) 393-396
3. Katz J.M., Lim W., Bridges C.B., et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 180 (1999) 1763-1770
4. Peiris J.S., Yu W.C., Leung C.W., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
5. WHO Communicable Disease. Surveillance and response, 2004-2006; http://www.who.int/csr/disease/avian_influenza.
6. Guan Y., Peiris J.S.M., Lipatov T.M., et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci 99 (2002) 8950-8955
7. Chen H., Deng G., Li Z., et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci 101 (2004) 10452-10457
8. Li K.S., Guan Y., Wang J., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 (2004) 209-213
9. Edwards L.E., Nguyen D.C., Lu X.H., et al. Antigenic characteristics of recent avian influenza A H5N1 viruses isolated from humans. Options of the control of influenza V (2004) p. 109-13
10. Horimoto T., Fukuda N., Iwatsuki-Horimoto K., et al. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 66 (2004) 303-305
11. The WHO Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11 (2005) 1515-1521
12. Takada A., Kuboki N., Okazaki K., et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 73 (1999) 8303-8307
13. Treanor J.J., Wilkinson B.E., Masseoud F., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
14. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
15. Li S., Liu C., Klimov A., et al. Recombinant influenza A virus vaccine for the pathogenic human A/Hong Kong/97(H5N1) viruses. J Infect Dis 179 (1999) 1132-1138
16. Subbarao K., Chen H., Swayne D., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003) 92-200
17. Webby R.J., Perez D.R., Coleman J.S., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 (2004) 1099-1103
18. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Efficacy of vaccination with live-attenuated, cold-adapted, trivalent intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 (2000) 168-175
19. Rudenko L.G., Lonskaya N.I., Klimov A.I., et al. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 74 (1996) 77-84
20. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181 (2000) 1133-1137
21. Treanor J.J., Kotloff K., Betts R.F., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18 (2000) 899-906
22. Kendal A.P., Maassab H.F., Alexandrova G.I., et al. Development of cold-adapted recombinant live, attenuated influenza a vaccines in the USA and USSR. Antiviral Res 1 (1981) 339-365
23. Desheva J.A., Rudenko L.G., Alexandrova G.I., et al. Reassortment between avian apathogenic and human attenuated cold-adapted viruses as an approach for preparing influenza pandemic vaccines. Options of the control of influenza V (2004) p. 724-27
24. Ghendon Y.Z., Polezhaev F.I., Lisovskaya K.V., et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 44 (1984) 730-733
25. Reed L.J., and Muench H. A simple method of estimation 50% endpoints. Am J Hyg 27 (1938) 493-497
26. Lu X.H., Tumpey T.M., Morken T., et al. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73 (1999) 5903-5911
27. Cox N.J., and Kendal A.P. Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers. J Infect Dis 149 (1984) 194-200
28. Katz J.M., Lu X., Young S.A., et al. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis 175 (1997) 352-363
29. Kendal A.P., Pereira M.S., and Skehel J. Concepts and procedures for laboratory-based influenza surveillance (1982), CDC, Atlanta p. B17-35
30. Rowe T., Abernathy R.A., Hu-Primmer J., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
31. Jones Y.L., and Swayne D.E. Comparative pathobiology of low and high pathogenicity H7N3 Chilean avian influenza viruses in chickens. Avian Dis 48 (2004) 119-128
32. Lu X.H., Cho D., Rowe T., et al. Pathogenicity and antigenicity of a new influenza A (H5N1) virus isolated from duck meat. J Med Virol 69 (2003) 553-559
33. Tumpey T.M., Renshaw M., Clements J.D., et al. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75 (2001) 5141-5150
34. Lu X, Edwards LE, Desheva JA, et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine, in press.
35. Couch R.B., Kasel J.A., Gerin J.L., et al. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129 (1974) 411-477
36. Kilbourne E.D., Pokorny B.A., Johansson B., et al. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 189 (2004) 459-461
37. Goto H., and Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 95 (1998) 10224-10228
38. Tumpey T.M., Basler C.F., Aguilar P.V., et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310 (2005) 77-80
39. Chen H., Matsuoka Y., Swayne D., et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21 (2003) 4430-4436
40. Monto A. Interrupting the transmission of respiratory tract infections: theory and practice. Clin Infect Dis 28 (1999) 200-204